BioMarin Pharmaceutical
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of BioMarin Pharmaceutical generated cash of $159,259,000, which is less than the previous year. Cash used in financing activities reached the amount of -$18,727,000 last year. Net change in cash is therefore $30,596,000.
Cash Flow
| 2014 | -73.53M | 194.55M | 185.68M |
|---|---|---|---|
| 2015 | -221.68M | -1.17B | 927.91M |
| 2016 | -227.83M | -484.04M | 727.10M |
| 2017 | -8.75M | -305.45M | 507.14M |
| 2018 | 20.20M | 264.35M | -388.00M |
| 2019 | 48.26M | -31.02M | -74.67M |
| 2020 | 85.36M | -53.62M | 181.11M |
| 2021 | 304.53M | -366.31M | -48K |
| 2022 | 175.90M | -20.02M | -18.65M |
| 2023 | 159.25M | -111.24M | -18.72M |
BMRN Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 724.53M | 587.27M | 649.15M | 437.44M | 493.98M | 598.02M | 408.33M | 397.04M | 875.48M | 568.78M |
Operating activities | ||||||||||
Net income | 167.64M | 141.56M | -64.08M | 859.1M | -23.84M | -77.21M | -117.04M | -630.21M | -171.79M | -133.96M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 104.38M | 101.96M | 108.03M | 105.17M | 105.3M | 95.67M | 87.86M | 96.91M | 47.18M | 56.74M |
Stock-based compensation expense | 207.09M | 196.30M | 197.26M | 189.71M | 159.86M | 0 | 140.26M | 134.64M | 111.52M | 88.23M |
| Deferred income tax benefit | 207.09M | 196.30M | 197.26M | 189.71M | 159.86M | 0 | 140.26M | 134.64M | 111.52M | 88.23M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -190.43M | -82.03M | 65.57M | -59.03M | -37.85M | -54.27M | -25.25M | -51.48M | -16.36M | -26.65M |
Inventories | -157.05M | -68.26M | -35.06M | -61.15M | -107.55M | -23.74M | -96.89M | -64.51M | -50.98M | -36.84M |
Accounts payable | 68.85M | 59.01M | 15.68B | -68.71M | 50.08M | 20.62M | 24.83M | -33.88M | 116.09M | 36.49M |
Cash generated by operating activities | 159.25M | 175.90M | 304.53M | 85.36M | 48.26M | 20.20M | -8.75M | -227.83M | -221.68M | -73.53M |
Investing activities | ||||||||||
Purchases Of Investments | -868.49M | -611.80M | -937.14M | -538.37M | -632.02M | -634.75M | -655.44M | -699.74M | -876.51M | -559.32M |
Investments In Property Plant And Equipment | -96.69M | -131.54M | -119.22M | -137.51M | -163.40M | -144.62M | -199.21M | -148.38M | -227.65M | -118.83M |
Acquisitions Net | 0 | 0 | -23.64M | -23.20M | 6.62M | 50M | 125M | -2.78M | -910.14M | -1.1M |
Cash generated by investing activities | -111.24M | -20.02M | -366.31M | -53.62M | -31.02M | 264.35M | -305.45M | -484.04M | -1.17B | 194.55M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 69.33M | 49.19M | 71.91M | 31.61M | 67.48M | 60.85M | 712.93M | 888.25M | 117.46M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -54.28M | -45.80M | -50M | -42.68M | -35.91M | -33.50M | -59.46M | 0 | -7.76M |
Repayments of term debt | -2.28M | -2.60M | -3.03M | -381.90M | -5.08M | -374.95M | 481.68M | 0 | 0 | -674K |
Cash used in financing activities | -18.72M | -18.65M | -48K | 181.11M | -74.67M | -388.00M | 507.14M | 727.10M | 927.91M | 185.68M |
Net Change In Cash | 30.59M | 137.25M | -61.88M | 211.71M | -56.53M | -104.04M | 189.69M | 11.29M | -478.44M | 306.70M |
Cash at end of period | 755.12M | 724.53M | 587.27M | 649.15M | 437.44M | 493.98M | 598.02M | 408.33M | 397.04M | 875.48M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |